Publication of OVM-200 Phase 1a results in Lancet group journal

The initial part of the Phase I trial of OVM-200, Oxford Vacmedix's lead cancer immunotherapy has been published in eClinical Medicine, a journal of the Lancet group.

Oxford, UK – 15th January 2026

Oxford Vacmedix (OVM), the UK-based biotech company developing novel immunotherapies to treat cancer is delighted to announce the publication of the Phase 1a results in eClinical Medicine, a journal of the Lancet group. The Phase 1 clinical trial of OVM-200, which is now nearing completion, is a multicentre, open-label, first-in-human evaluation of OVM-200, an immunotherapy developed using Oxford Vacmedix's Recombinant Overlapping Peptide (ROP) therapeutic platform. Patients with advanced non-small cell lung cancer, ovarian cancer, or prostate cancer are being treated in the trial. In Phase 1a 12 patients received three subcutaneous doses (250, 500, 1,000, or 2,000µg) of OVM-200 at 2-week intervals.

The results demonstrate very good progress toward the primary and secondary endpoints for the trial;

- **Excellent Safety Profile** (primary endpoint): OVM-200 is very well tolerated at all dose levels. There have been no serious adverse drug reactions and no dose-limiting toxicities. The only adverse effects were Grade 1 injection-site reactions.

- **Very strong Immunogenicity** (secondary endpoint): the immune response for both antibodies and T cells has been measured. Both measurements showed a very strong immune response with the antibody response being sustained over 6 months. The 2,000µg cohort generated the strongest immune response.

- **Therapeutic Dose established for Phase 1b:** based on the immune response seen the 2,000µg dose was chosen for the Phase 1b continuation of the trial. Patients could receive up to 11 doses of 2,000µg in Phase 1b.

Professor Shisong Jiang, founder and Chief Scientific Officer of Oxford Vacmedix, said:

"We are very pleased to have this publication of the first clinical results for immunotherapies developed using our ROP technology - our first step toward providing accessible immunotherapy for all patient types. This progress has only been possible through the hard work of many people in the labs and in the clinic."

William Finch, Chief Executive Officer of Oxford Vacmedix, said:

"This publication marks an important milestone for the company and shows the potential of the ROP technology. We are very pleased with the results and with the trial now nearing completion are already in discussion with potential Series B investors to fund Phase 2 trials for OVM-200".

Oxford Vacmedix UK
The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK
T +44 (0)1865 742087 **E** enquiries@oxfordvacmedix.com www.oxfordvacmedix.com

END

For more information or to express an interest in investing in Series B please contact:

William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 742087 | M: +44(0)7769 903711 | E: wfinch@oxfordvacmedix.com

Dr Nam Park, Chief Business Officer, Oxford Vacmedix
T: +44 (0)1865 742087 | M: +44(0)7932 613938 | E: npark@oxfordvacmedix.com

Notes to Editor

About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a biotech company spun out from the University of Oxford's Department of Oncology. The company is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Professor Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell and antibody immunity therefore forming a good platform for therapeutic immunotherapy and diagnostics in cancer and infectious diseases.

The technology uses the ROP technology to design and develop therapeutic cancer immunotherapies and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and in infectious diseases.

OVM is developing two lead immunotherapies, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours including prostate, ovarian and non-small cell lung cancer (NSCLC). Both immunotherapies will be tested as single agents and in combination with IO agents. OVM has a strong pipeline, with a diagnostic for anti-microbial resistance being tested and one other cancer immunotherapy for pancreatic cancer also in preclinical development.

The company is currently seeking Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and in combination. In addition the option of using MRNA delivery with the ROP technology will be explored.

For more information: http://www.oxfordvacmedix.com